The drug's prevention efficacy was 76% in the 450-mg group, 61% in the 300-mg group, and 58% in the 150-mg group.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
Median cumulative state rates ranged from 23 (Alaska) to 249 (New York) per 100,000 people.
The CDC says it's now classifying the flu season as high severity for all age-groups for the first time since the 2017-18 season.
Test positivity topped 30%, with steady rises in emergency department visits and hospitalizations.
Median hospital stay was longer in the RSV group than in flu patients.
Oseltamivir recipients had an 18% lower risk of 30-day mortality.
The highest rates of influenza A/B (21%), influenza A (17%), and influenza B (20%) were observed in Asia and Europe.
Sixteen more flu deaths were reported in children, with virus activity at high or very high flu levels across much of the nation.
By 180 days, the COVID-19 death rate reached 3.1% in the 2022-23 season and 2.9% in the 2023-24 season.
Both oseltamivir and baloxivir have a role in the treatment of flu, the healthcare professionals say.
Experts fear the move could undercut US and global efforts to monitor and respond to infectious disease outbreaks.
